These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease. Akhtar RS; Licata JP; Luk KC; Shaw LM; Trojanowski JQ; Lee VM J Neurochem; 2018 Jun; 145(6):489-503. PubMed ID: 29500813 [TBL] [Abstract][Full Text] [Related]
44. α-Synuclein in blood cells differentiates Parkinson's disease from healthy controls. Abd Elhadi S; Grigoletto J; Poli M; Arosio P; Arkadir D; Sharon R Ann Clin Transl Neurol; 2019 Dec; 6(12):2426-2436. PubMed ID: 31742923 [TBL] [Abstract][Full Text] [Related]
46. α-Synuclein Oligomer Detection with Aptamer Switch on Reduced Graphene Oxide Electrode. Jang SJ; Lee CS; Kim TH Nanomaterials (Basel); 2020 Apr; 10(5):. PubMed ID: 32349285 [TBL] [Abstract][Full Text] [Related]
47. Magnetic field-assisted SPR biosensor based on carboxyl-functionalized graphene oxide sensing film and Fe3O4-hollow gold nanohybrids probe. Wu Q; Sun Y; Zhang D; Li S; Wang X; Song D Biosens Bioelectron; 2016 Dec; 86():95-101. PubMed ID: 27336617 [TBL] [Abstract][Full Text] [Related]
48. α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. Yanamandra K; Gruden MA; Casaite V; Meskys R; Forsgren L; Morozova-Roche LA PLoS One; 2011 Apr; 6(4):e18513. PubMed ID: 21541339 [TBL] [Abstract][Full Text] [Related]
49. Electrochemiluminescent aptamer-sensor for alpha synuclein oligomer based on a metal-organic framework. Wu Q; Tan R; Mi X; Tu Y Analyst; 2020 Mar; 145(6):2159-2167. PubMed ID: 32129373 [TBL] [Abstract][Full Text] [Related]
50. Au nanoparticles as label-free competitive reporters for sensitivity enhanced fiber-optic SPR heparin sensor. Yuan H; Ji W; Chu S; Liu Q; Guang J; Sun G; Zhang Y; Han X; Masson JF; Peng W Biosens Bioelectron; 2020 Apr; 154():112039. PubMed ID: 32056956 [TBL] [Abstract][Full Text] [Related]
51. Salivary alpha-synuclein in the diagnosis of Parkinson's disease and Progressive Supranuclear Palsy. Vivacqua G; Suppa A; Mancinelli R; Belvisi D; Fabbrini A; Costanzo M; Formica A; Onori P; Fabbrini G; Berardelli A Parkinsonism Relat Disord; 2019 Jun; 63():143-148. PubMed ID: 30796010 [TBL] [Abstract][Full Text] [Related]
52. Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis. Bougea A; Stefanis L; Paraskevas GP; Emmanouilidou E; Vekrelis K; Kapaki E Neurol Sci; 2019 May; 40(5):929-938. PubMed ID: 30715632 [TBL] [Abstract][Full Text] [Related]
53. Fe Chen F; Wu Q; Song D; Wang X; Ma P; Sun Y Colloids Surf B Biointerfaces; 2019 May; 177():105-111. PubMed ID: 30711758 [TBL] [Abstract][Full Text] [Related]
54. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease. Sharma N; Rao SP; Kalivendi SV Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974 [TBL] [Abstract][Full Text] [Related]
55. Alpha-Synuclein Dopaminylation Presented in Plasma of Both Healthy Subjects and Parkinson's Disease Patients. Zhao H; Huang S; Palanisamy S; Wang C; Rainer G; Zhang X Proteomics Clin Appl; 2020 Sep; 14(5):e1900117. PubMed ID: 32538547 [TBL] [Abstract][Full Text] [Related]
56. Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Visanji NP; Marras C; Hazrati LN; Liu LW; Lang AE Mov Disord; 2014 Apr; 29(4):444-50. PubMed ID: 24375496 [TBL] [Abstract][Full Text] [Related]
57. Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease. von Euler Chelpin M; Söderberg L; Fälting J; Möller C; Giorgetti M; Constantinescu R; Blennow K; Zetterberg H; Höglund K J Parkinsons Dis; 2020; 10(4):1429-1442. PubMed ID: 33016895 [TBL] [Abstract][Full Text] [Related]
58. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models. Weihofen A; Liu Y; Arndt JW; Huy C; Quan C; Smith BA; Baeriswyl JL; Cavegn N; Senn L; Su L; Marsh G; Auluck PK; Montrasio F; Nitsch RM; Hirst WD; Cedarbaum JM; Pepinsky RB; Grimm J; Weinreb PH Neurobiol Dis; 2019 Apr; 124():276-288. PubMed ID: 30381260 [TBL] [Abstract][Full Text] [Related]
59. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. Games D; Valera E; Spencer B; Rockenstein E; Mante M; Adame A; Patrick C; Ubhi K; Nuber S; Sacayon P; Zago W; Seubert P; Barbour R; Schenk D; Masliah E J Neurosci; 2014 Jul; 34(28):9441-54. PubMed ID: 25009275 [TBL] [Abstract][Full Text] [Related]
60. Ultra-sensitive detection by metal nanoparticles-mediated enhanced SPR biosensors. Fathi F; Rashidi MR; Omidi Y Talanta; 2019 Jan; 192():118-127. PubMed ID: 30348366 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]